INS and obesity disorder: Since it has been suggested that GM3 is involved in the pathophysiological changes associated with obesity and/or metabolic disorders by inhibiting insulin signaling [14, 15], we originally expected that DKO mice, which were unable to produce all gangliosides except GM3 systemically, would exhibit severe metabolic disorders due to insulin dysfunction.